Effect of glucagon-like peptide-1 receptor agonists on circulating levels of leptin and resistin: A meta-analysis of randomized controlled trials

Liraglutide Treatment in Overweight and Obese Patients with Type 1 Diabetes: A 26 weeks Randomized Controlled Trial

(2020) Husam Ghanim et al.   DIABETES OBESITY & METABOLISM

Relevance of Leptin and Other Adipokines in Obesity-Associated Cardiovascular Risk

(2019) Manuel F. Landecho et al.   Nutrients

Adipokine dysregulation and adipose tissue inflammation in human obesity

(2018) Xabier Unamuno et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

The role of adipose tissue in cardiovascular health and disease

(2018) Evangelos K. Oikonomou et al.   Nature Reviews Cardiology

GLP-1 Improves Adipocyte Insulin Sensitivity Following Induction of Endoplasmic Reticulum Stress

(2018) Yaojing Jiang et al.   Frontiers in Pharmacology

Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trial

(2017) Li Shi et al.   Obesity Research & Clinical Practice

A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus

(2017) Huibiao Quan et al.   Experimental and Therapeutic Medicine

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis

(2016) Matthew J. Armstrong et al.   JOURNAL OF HEPATOLOGY

Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study

(2016) Olivia M. Farr et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Revisiting the adipocyte: a model for integration of cytokine signaling in the regulation of energy metabolism

(2015) Amaia Rodríguez et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Liraglutide treatment causes upregulation of adiponectin and downregulation of resistin in Chinese type 2 diabetes

(2015) Dongmei Li et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

(2015) Xiang Wan et al.   BMC Medical Research Methodology

Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers

(2014) Eren Gurkan et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss

(2014) E W Iepsen et al.   INTERNATIONAL JOURNAL OF OBESITY

Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study

(2014) Yumie Takeshita et al.   Journal of Diabetes Investigation

Variation in Inflammatory Markers and Glycemic Parameters After 12 Months of Exenatide Plus Metformin Treatment Compared with Metformin Alone: A Randomized Placebo-Controlled Trial

(2013) Giuseppe Derosa et al.   PHARMACOTHERAPY

Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes

(2012) Y.-S. Lee et al.   DIABETOLOGIA

Resistin: functional roles and therapeutic considerations for cardiovascular disease

(2011) Md S Jamaluddin et al.   BRITISH JOURNAL OF PHARMACOLOGY

Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition

(2010) M. C. Bunck et al.   DIABETES CARE

Exenatide Versus Glibenclamide in Patients with Diabetes

(2010) G. Derosa et al.   Diabetes Technology & Therapeutics